Introduction
The pro-inflammatory cytokines interleukin-1 (IL-1) and tumour necrosis factor (TNF) are potent molecular mediators with wide-ranging effects on a large array of cells, tissues and organs. 1'2 They are produced by a wide variety of cell types, but monocytes-macrophages are the major source of these polypeptides which share structural similarities and have overlapping activities. 3 '4 They have been implicated in the pathogenesis of chronic inflammatory (e.g. rheumatoid arthritisS), auto- immune (e.g. insulin-dependent diabetes mellitus6), allergic (e.g. asthma7), infectious (e.g. leprosys) and malignant (e.g. ovarian carcinoma 9) diseases.
There is therefore a great interest in drugs that can control their generation and/or action because of the potential for therapeutic application. It has recently been shown that tetrandrine, a novel bisbenzylisoquinoline alkaloid, has potent in- (C) 1993 Rapid Communications of Oxford Ltd hibitory effects on the production of IL-lfl and TNFcz by human monocyte-macrophage cultures. [1] [2] In addition, it has been shown to have therapeutic efficacy in a number of animal models of human disease, such as relapsing experimental allergic encephalitis in rats (multiple sclerosis), 13 spontaneous diabetes in BB rats (insulin-dependent diabetes mellitus), 4 air-pouch inflammation in rats (rheumatoid arthritis) is and airways microvascular leakage in guinea-pigs (asthma). 16 In an attempt to gain some mechanistic insight into the relationship between the bisbenzylisoquinoline structure and the extent of inhibition of the synthesis of TNF-z and IL-lfl, the inhibitory potencies of tetrandrine and a series of ten other bisbenzylisoquinolines and one benzylisoquinoline (half-molecule) are now compared. The 
